NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the “Company”) , has entered into definitive agreements to sell 8 million shares of its common stock at a price per share of $2.50 pursuant to a registered direct offering to several select institutional investors, representing gross proceeds of approximately $20 million.
Commenting on the transaction, Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, stated, “We are extremely pleased to have consummated this transaction, raising $20 million for Keryx. We believe that following this offering we will have sufficient capital to complete the Phase 3 programs for Perifosine and Zerenex.”
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The shares of common stock may only be offered by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus can be obtained from the SEC’s website at http://www.sec.gov.
Forward Looking Statement
Keryx Biopharmaceuticals, Inc.
